Jul 2026· Cell Death and Differentiation· 0 citations· 31 references
Medicine
TL;DR
This perspective brings together multiple observations concerning the regulatory architecture and functional interactions of the TP53 gene and its isoforms to cooperate to maintain an open chromatin state in the P2 region in a manner reminiscent of a neural "associative memory" network.
Abstract
This perspective brings together multiple observations concerning the regulatory architecture and functional interactions of the TP53 gene and its isoforms. The TP53 gene encompasses an internal enhancer-promoter region (P2) located between exons 2 and 5, which is transactivated by full-length TAp53α, to drive the expression of truncated TP53 isoforms ΔN133p53α, β or γ. ΔN133p53α homo-monomers or dimers very likely form hetero-tetramers with homo-dimers of full-length TAp53α. The TAp53α-ΔN133p53 tetramer then acts as a transcription factor augmenting mitochondrial efficiency, DNA repair, telomere restoration and reversing cellular senescence, thus opposing many outputs of tumor suppressive TAp53α homo-tetramers. Other transcription factors, such as estrogen receptor (ER), OCT1, and SOX9 also may bind the P2 promoter-enhancer to promote transcription of oncogenic TP53 isoforms. These transcription factors, together with full-length TAp53α, appear to cooperate to maintain an open chromatin state in the P2 region in a manner reminiscent of a neural "associative memory" network.
An integrated overview of the molecular features and functional roles of BAP1 is provided, with particular emphasis on its impacts on the regulation of cell death including apoptosis, ferroptosis and disulfidptosis.
Kexin Fan, Jun Yao, Shaobo Wu et al.· Frontiers in Cell and Develo...· 0 citations
This study uncovers a therapeutic vulnerable lncRNA-centric circuitry and provides compelling preclinical evidence for the development and application of a novel RNA targeting-LNP based therapy for treatment of myeloid leukemia.
Zhenggen Jin, Brendan D. Ma, Karen Y. T. Chan et al.· bioRxiv· 0 citations
It is found that p53 upregulates ITM2A expression, while ITM2A in turn inhibits p53 function, suggesting a negative feedback loop and suggesting ITM2A as a potential prognostic marker and therapeutic target for cancers with dysregulated p53 signaling.
Sim Namkoong, Min-Su Jang, Jeong‐In Lee et al.· Cell Cycle· 0 citations
This review summarizes current knowledge regarding the molecular biology of TTP and HuR, emphasizing their opposing functions in mRNA metabolism and cancer progression; discusses mechanisms regulating their expression, localization, phosphorylation, and RNA-binding activity; analyze cancer-specific evidence; and examin...
R. Lotti, Tommaso Selmi, Alexis Grande et al.· Frontiers in Oncology· 0 citations
These findings establish CTD-2566 J3.1 as a multifunctional enhancer-associated lncRNA (e-lncRNA) that orchestrates key oncogenic processes in luminal breast cancer and underscores the utility of three-dimensional culture systems to reveal context-specific lncRNA functions.
Stephanie I. Nuñez-Olvera, L. R. Hernández-Barrientos, Elia Martínez-Baeza et al.· International Journal of Bio...· 0 citations
Insight is provided into IRES-mediated translation of Δ160p53, which can be considered a novel target for cancer treatment and its role in cancer regulation.
P. K. Ghosh, Piyanki Das, Sahana Ghosh et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.